Tnf Pharmaceuticals Inc (TNFA)

$3.74 +0.44 (13.35%)
Market Cap 5.89M
Revenue (ttm) 0.00
Net Income (ttm) -23.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 735,825
Avg Vol 708,828
Day's Range N/A - N/A
Shares Out 1.79M
Stochastic %K 1%
Beta 2.04
Analysts Strong Buy
Price Target N/A

Company Profile

TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analo...

Industry: Biotechnology
Sector: Healthcare
Phone: 856 848 8698
Address:
1185 Avenue of the Americas, Suite 249, New York, United States
ka1954
ka1954 Sep. 8 at 7:37 PM
$TNFA chinese junk stock SNTG went 500% so easily, but this fucker just can't do anything
1 · Reply
shavitmi
shavitmi Sep. 8 at 7:34 PM
$TNFA read about lightsolver!!! we are into the Quntom business $RGTI $QBTS
0 · Reply
shavitmi
shavitmi Sep. 8 at 7:32 PM
$TNFA added
0 · Reply
Schizoo
Schizoo Sep. 8 at 7:28 PM
$TNFA 🤌🚀
0 · Reply
Schizoo
Schizoo Sep. 8 at 7:27 PM
$TNFA
0 · Reply
yl_trader
yl_trader Sep. 8 at 7:21 PM
$TNFA presented today, news pending.
0 · Reply
yl_trader
yl_trader Sep. 8 at 7:19 PM
$TNFA yep...warming up
0 · Reply
yl_trader
yl_trader Sep. 8 at 7:12 PM
$TNFA this is a solid. I'm in
0 · Reply
TraderJay85
TraderJay85 Sep. 8 at 7:11 PM
$TNFA adding here. i also think this one is expecting news soon on a fast track from fda. do your own DD though.
0 · Reply
shavitmi
shavitmi Sep. 8 at 7:10 PM
$TNFA if we ger recognized as a quantom stock cause the deal with lightsolver this is 10 bagger
0 · Reply
Latest News on TNFA
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 9:15 AM EDT - 6 hours ago

TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

TNF Pharmaceuticals Announces Closing of $7 Million Private Placement

Sep 4, 2025, 9:15 AM EDT - 4 days ago

TNF Pharmaceuticals Announces Closing of $7 Million Private Placement

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

Sep 2, 2025, 9:20 AM EDT - 6 days ago

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

PMCB

TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications

Sep 2, 2025, 9:15 AM EDT - 6 days ago

TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications

TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

Aug 28, 2025, 9:15 AM EDT - 11 days ago

TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

Aug 19, 2025, 5:20 PM EDT - 19 days ago

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

Jun 24, 2025, 9:15 AM EDT - 2 months ago

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

May 8, 2025, 9:20 AM EDT - 4 months ago

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

Apr 22, 2025, 9:15 AM EDT - 4 months ago

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025

Apr 16, 2025, 9:15 AM EDT - 5 months ago

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

Mar 17, 2025, 9:15 AM EDT - 6 months ago

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

Mar 5, 2025, 9:00 AM EST - 6 months ago

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

Feb 25, 2025, 9:20 AM EST - 6 months ago

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

Jan 29, 2025, 9:15 AM EST - 7 months ago

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Jan 15, 2025, 9:15 AM EST - 8 months ago

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

Dec 19, 2024, 9:15 AM EST - 9 months ago

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

Dec 9, 2024, 9:00 AM EST - 9 months ago

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

Oct 2, 2024, 9:10 AM EDT - 1 year ago

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

Aug 21, 2024, 9:00 AM EDT - 1 year ago

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

Jul 24, 2024, 9:05 AM EDT - 1 year ago

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

Jul 22, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

Jun 17, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Secures Strategic Investments

PMCB

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

May 21, 2024, 9:00 AM EDT - 1 year ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PMCB

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Mar 5, 2024, 9:15 AM EST - 1 year ago

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Feb 13, 2024, 11:45 AM EST - 1 year ago

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug

Dec 29, 2023, 12:45 PM EST - 1 year ago

MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

Dec 6, 2023, 9:15 AM EST - 1 year ago

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

Oct 19, 2023, 9:00 AM EDT - 2 years ago

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023

Oct 4, 2023, 7:30 AM EDT - 2 years ago

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023

FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

Aug 14, 2023, 8:30 AM EDT - 2 years ago

FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

Aug 2, 2023, 8:30 AM EDT - 2 years ago

MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

Jul 31, 2023, 9:00 AM EDT - 2 years ago

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Apr 12, 2023, 8:30 AM EDT - 2 years ago

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

Mar 20, 2023, 8:55 AM EDT - 2 years ago

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

Mar 8, 2023, 8:30 AM EST - 2 years ago

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

Mar 2, 2023, 8:30 AM EST - 2 years ago

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Feb 28, 2023, 8:30 AM EST - 2 years ago

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

MyMD Announces $15 Million Offering with Existing Investors

Feb 21, 2023, 8:45 AM EST - 2 years ago

MyMD Announces $15 Million Offering with Existing Investors

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Dec 6, 2022, 9:40 AM EST - 2 years ago

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Dec 6, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Nov 17, 2022, 8:00 AM EST - 3 years ago

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Nov 14, 2022, 8:00 AM EST - 3 years ago

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

Aug 30, 2022, 8:30 AM EDT - 3 years ago

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Aug 3, 2022, 9:45 AM EDT - 3 years ago

Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Jul 26, 2022, 7:30 AM EDT - 3 years ago

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

Jul 12, 2022, 9:30 AM EDT - 3 years ago

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Jun 21, 2022, 10:30 AM EDT - 3 years ago

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

Apr 12, 2022, 9:30 AM EDT - 3 years ago

MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

ka1954
ka1954 Sep. 8 at 7:37 PM
$TNFA chinese junk stock SNTG went 500% so easily, but this fucker just can't do anything
1 · Reply
shavitmi
shavitmi Sep. 8 at 7:34 PM
$TNFA read about lightsolver!!! we are into the Quntom business $RGTI $QBTS
0 · Reply
shavitmi
shavitmi Sep. 8 at 7:32 PM
$TNFA added
0 · Reply
Schizoo
Schizoo Sep. 8 at 7:28 PM
$TNFA 🤌🚀
0 · Reply
Schizoo
Schizoo Sep. 8 at 7:27 PM
$TNFA
0 · Reply
yl_trader
yl_trader Sep. 8 at 7:21 PM
$TNFA presented today, news pending.
0 · Reply
yl_trader
yl_trader Sep. 8 at 7:19 PM
$TNFA yep...warming up
0 · Reply
yl_trader
yl_trader Sep. 8 at 7:12 PM
$TNFA this is a solid. I'm in
0 · Reply
TraderJay85
TraderJay85 Sep. 8 at 7:11 PM
$TNFA adding here. i also think this one is expecting news soon on a fast track from fda. do your own DD though.
0 · Reply
shavitmi
shavitmi Sep. 8 at 7:10 PM
$TNFA if we ger recognized as a quantom stock cause the deal with lightsolver this is 10 bagger
0 · Reply
shavitmi
shavitmi Sep. 8 at 7:04 PM
$TNFA lightsolver is an israeli company established in weizman institute!!!!
0 · Reply
shavitmi
shavitmi Sep. 8 at 6:54 PM
$TNFA This technology enables the simultaneous scanning of all possible solutions, mimicking the power of quantum computing and providing solutions to problems that are beyond the capabilities of classical and quantum computers. $RGTI
0 · Reply
shavitmi
shavitmi Sep. 8 at 6:52 PM
$TNFA entering the Quantom business, and no one knows it yet exclusive rights for lightsolver: https://lightsolver.com/about-us/ $OCTO
1 · Reply
Schizoo
Schizoo Sep. 8 at 6:38 PM
$TNFA they should unvest in crypto so we can skyrocket like $OCTO 🤞🤌🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
TraderJay85
TraderJay85 Sep. 8 at 6:35 PM
$TNFA i took half a position here at 3.85. ill buy all dips until full position.
2 · Reply
TraderJay85
TraderJay85 Sep. 8 at 6:32 PM
$TNFA these are the plays im talking about. bottomed and curling. almost always guaranteed win. beautiful set up
0 · Reply
Schizoo
Schizoo Sep. 8 at 6:25 PM
$TNFA BALLS N PATIENCE PEOPLE
1 · Reply
MilitaryVetTrader
MilitaryVetTrader Sep. 8 at 6:24 PM
$TNFA The amateur 🐻 who used to be in here paying every minute sure have been quiet the past few days 🦗
1 · Reply
JL_TradeZ
JL_TradeZ Sep. 8 at 6:20 PM
$TNFA ww
0 · Reply
Mack43
Mack43 Sep. 8 at 6:12 PM
$TNFA Climbing....
1 · Reply
TNFA_BLSH_buying_EVRYDIP
TNFA_BLSH_buying_EVRYDIP Sep. 8 at 6:09 PM
$TNFA if someone still waiting ?? Yes you can 🚀 don’t forget to buy every dip 😁😁
0 · Reply
SwingDaily
SwingDaily Sep. 8 at 6:09 PM
$LIMN patience pays off places like this. $IXHL $ASST $TBH $TNFA
0 · Reply